DelMar Pharma

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc.

DelMar Announces $19.6 Million Private Placement Priced At-The-Market

SAN DIEGO, Aug. 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc.

DelMar Announces Approval of Merger by Stockholders

SAN DIEGO, July 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today that it will be conducting a conference call to discuss the.

DelMar Pharmaceuticals to Host Conference Call to Discuss Proposed Acquisition of Adgero Pharmaceuticals

Shares of nano-cap biopharma DelMar Pharmaceuticals Inc (NASDAQ: DMPI) are trading sharply higher on over 40 times average volume.

Here Is What's Driving The Rally In DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q3 2019 Results - Earnings Call Transcript

News for DelMar Pharma Stock (DMPI)